Study findings updated . AI-assisted evidence summary, not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY1 in 7 at age 85From the estimated 15% infection fatality rate at age 85, pooled 2020 data
COVID-19 death risk climbed from 1.4% at 65 to 15% at 85.
Researchers pooled antibody surveys and contact-tracing data to estimate the infection fatality rate: the share of all infected people, including mild and undiagnosed cases, who died. It rose exponentially with age: 0.4% at 55, 1.4% at 65, 4.6% at 75 and 15% at 85, topping 25% at 90 and older.
Age, more than anything else, set the danger. An infection that barely threatened a teenager could kill a great-grandparent, so shielding the oldest from infection could cut total deaths substantially. These pooled estimates come from 2020, before vaccines or effective treatments existed, so they describe the pandemic's first year, not today.
See the evidence
A systematic review and meta-analysis of population antibody surveys and national contact-tracing programs from 2020, mostly in Europe, the US and Asia-Pacific countries.
From the study: “rises to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, 15% at age 85, and exceeds 25% for ages 90 and above”
1 in 7 at age 85
Levin AT et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. European journal of epidemiology. 2020.
From the study: “Our analysis finds a exponential relationship between age and IFR for COVID-19.”
1 in 7 at age 85
Levin AT et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. European journal of epidemiology. 2020.
From the study: “Consequently, public health measures to mitigate infections in older adults could substantially decrease total deaths.”
1 in 7 at age 85
Levin AT et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. European journal of epidemiology. 2020.
Many older adults with COVID-19 arrived confused, often without fever.
28% arrived confusedOlder adults with COVID-19 who had delirium on arrival at US emergency rooms
Among 817 older adults with COVID-19 seen in US emergency departments, 28% had delirium (sudden confusion or reduced alertness), making it the sixth most common sign. Of those with delirium, 37% had no fever or shortness of breath. Delirium was linked to higher rates of intensive care and death, compared with patients without it.
In an older person, new confusion or unusual drowsiness can be the first or only sign of COVID-19. Waiting for a fever or a cough could mean missing the infection. Delirium was identified by reviewing medical records after the fact at 7 US sites in 2020, so some cases were likely missed.
See the evidence
A multicenter records study of 817 consecutive older adults with COVID-19 at 7 US emergency departments, beginning in March 2020.
From the study: “A total of 226 patients (28%) had delirium at presentation, and delirium was the sixth most common of all presenting symptoms and signs.”
28% arrived confused
Kennedy M et al. Delirium in Older Patients With COVID-19 Presenting to the Emergency Department. JAMA network open. 2020.
From the study: “In this cohort study of 817 older adults with COVID-19 presenting to US emergency departments, delirium was common and often was seen without other typical symptoms or signs.”
28% arrived confused
Kennedy M et al. Delirium in Older Patients With COVID-19 Presenting to the Emergency Department. JAMA network open. 2020.
Older adults who took Paxlovid had far fewer COVID-19 hospitalizations.
73% fewer admissionsFrom hazard ratio 0.27 for COVID-19 hospitalization, treated vs untreated adults 65+
During Israel's Omicron surge, high-risk adults 65 and older who took nirmatrelvir (the main drug in Paxlovid) had 14.7 COVID-19 hospitalizations per 100,000 person-days versus 58.9 among untreated eligible peers, a 73% lower risk after adjustment. COVID-19 deaths were also lower. No benefit was seen in younger adults. Only 6% of eligible older patients got the drug.
The people most likely to end up in the hospital appeared to gain the most from this pill, yet very few of those eligible actually received it. This was an observational study, not a randomized trial, so differences between who did and did not get the drug may explain part of the gap.
See the evidence
A health-records study of 109,254 high-risk adults 40 and older with COVID-19 in Israel's largest health plan during the early-2022 Omicron surge.
From the study: “hospitalization due to Covid-19 occurred in 11 treated patients (14.7 cases per 100,000 person-days) and in 766 untreated patients (58.9 cases per 100,000 person-days)”
73% fewer admissions
Arbel R et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. The New England journal of medicine. 2022.
In 2020, deaths rose 26% among Medicare seniors with dementia, 12% without.
26% higher death rateAdjusted death rate, 2020 vs 2019, older Medicare enrollees with dementia
Among older Medicare enrollees, adjusted 2020 death rates were 25.7% above 2019 for those with Alzheimer disease or related dementias, versus 12.4% for others. In regions with the fewest COVID-19 infections, people without dementia had no excess deaths, but deaths rose 8.8% for people with dementia at home and 14.2% in nursing homes. Asian, Black and Hispanic people with dementia fared worst.
Dementia made older adults far more vulnerable in the pandemic's first year, even where the virus was scarce, hinting at harms from disrupted care as well as from infection itself. This comparison of 2020 with 2019 cannot separate deaths from COVID-19 itself from deaths tied to disrupted care or other pandemic changes.
See the evidence
A national study comparing 2019 and 2020 death rates among all fee-for-service Medicare enrollees 65 and older, roughly 27 million people each year.
From the study: “Compared with 2019, adjusted mortality in 2020 was 12.4% (95% CI, 12.1%-12.6%) higher among enrollees without ADRD and 25.7% (95% CI, 25.3%-26.2%) higher among all enrollees with ADRD”
26% higher death rate
Gilstrap L et al. Trends in Mortality Rates Among Medicare Enrollees With Alzheimer Disease and Related Dementias Before and During the Early Phase of the COVID-19 Pandemic. JAMA neurology. 2022.
From the study: “The hospital referral region in the lowest quintile for COVID-19 infections in 2020 had no excess mortality among enrollees without ADRD but 8.8%”
26% higher death rate
Gilstrap L et al. Trends in Mortality Rates Among Medicare Enrollees With Alzheimer Disease and Related Dementias Before and During the Early Phase of the COVID-19 Pandemic. JAMA neurology. 2022.
From the study: “14.2% (95% CI, 12.2%-16.2%) higher mortality among enrollees with ADRD living in nursing homes”
26% higher death rate
Gilstrap L et al. Trends in Mortality Rates Among Medicare Enrollees With Alzheimer Disease and Related Dementias Before and During the Early Phase of the COVID-19 Pandemic. JAMA neurology. 2022.
Extra deaths among older Americans with dementia fell 77% in year two.
Excess deaths fell 77%Drop in dementia-related excess deaths, US adults 65+, pandemic year 2 vs year 1
Researchers compared deaths of older Americans whose death certificates listed Alzheimer disease or related dementias with deaths expected from pre-pandemic trends. The excess shrank 77% from the first pandemic year to the second. In nursing homes, these deaths fell below expected levels after vaccine rollout, but excess deaths at home stayed high.
The dementia death toll was not locked in: it eased sharply in nursing homes after vaccines arrived. People with dementia living at home did not see the same relief. This death-certificate trend analysis shows timing, not cause, so it cannot prove that vaccines drove the decline.
See the evidence
An analysis of about 2.3 million US death certificates listing dementia among people 65 and older, comparing March 2020 to February 2022 with trends since 2014.
From the study: “The pandemic-era excess in ADRD-related deaths thus declined by 77% from year 1 to year 2.”
Excess deaths fell 77%
Chen R et al. Excess Mortality With Alzheimer Disease and Related Dementias as an Underlying or Contributing Cause During the COVID-19 Pandemic in the US. JAMA neurology. 2023.
From the study: “After vaccine rollout began, ADRD-related deaths in NH/LTC settings declined significantly, with lower than expected deaths throughout the Delta wave and most of the Omicron wave.”
Excess deaths fell 77%
Chen R et al. Excess Mortality With Alzheimer Disease and Related Dementias as an Underlying or Contributing Cause During the COVID-19 Pandemic in the US. JAMA neurology. 2023.
From the study: “In contrast, ADRD-related deaths occurring at home remained high throughout year 2 of the pandemic, even after vaccine rollout began.”
Excess deaths fell 77%
Chen R et al. Excess Mortality With Alzheimer Disease and Related Dementias as an Underlying or Contributing Cause During the COVID-19 Pandemic in the US. JAMA neurology. 2023.
Nursing home residents' updated shot guarded against hospitalization or death, then faded.
77% protectionAgainst hospitalization or death at 12 weeks after the KP.2 shot, VA nursing homes
Among long-stay residents of Veterans Affairs nursing homes in fall 2024, those who got the updated KP.2 vaccine had 77% protection against COVID-19 hospitalization or death at 12 weeks versus matched residents not vaccinated during the study, falling to 53% by week 18. Protection against infection was weaker and faded faster: 38% at 12 weeks, 4% at 18.
An updated shot still shielded frail older residents from the worst outcomes, but the benefit shrank within months, raising the question of how often this group needs a dose. This was an observational study in VA nursing homes, where residents were almost all men, so results may differ in other nursing homes.
See the evidence
A trial-mimicking comparison of 1,711 matched pairs of vaccinated and unvaccinated long-stay residents in Veterans Affairs nursing homes, starting in fall 2024.
From the study: “Vaccine effectiveness against hospitalization or death was 77% at week 12 (95% CI, 60%-90%) and 53% at week 18 (95% CI, 21%-71%).”
77% protection
Gravenstein S et al. Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination. Journal of the American Medical Directors Association. 2026.
From the study: “Vaccine effectiveness against COVID-19 infection was 38% at week 12 (95% CI, 13%-56%) and 4% at week 18 (95% CI, -30 to 29%).”
77% protection
Gravenstein S et al. Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination. Journal of the American Medical Directors Association. 2026.
From the study: “Long-stay residents living in Veterans Affairs nursing homes between September 18, 2024, and October 30, 2024.”
77% protection
Gravenstein S et al. Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination. Journal of the American Medical Directors Association. 2026.
Only 31% of older adults' outpatient COVID-19 visits ended with an antiviral.
Only 31% got antiviralsUS outpatient COVID-19 visits by adults 65+ with an antiviral prescribed, 2023–2025
In electronic records from US health systems, an antiviral was prescribed at 31% of 482,456 outpatient COVID-19 visits by adults 65 and older. Prescribing fell to 16%–23% when COVID-19 was less common, versus 37%–38% during surges. People with at least one chronic illness and rural residents were less likely to get a prescription.
Most older adults diagnosed with COVID-19 left without an antiviral, and rural patients and those with chronic illnesses were the most likely to miss out. This records study counts visits rather than people and cannot show why an antiviral was not prescribed in a given case.
See the evidence
A CDC analysis of electronic health records from US health systems for adults 65 and older diagnosed with COVID-19 in outpatient care, June 2023 to September 2025.
From the study: “A total of 482,456 patient encounters with a COVID-19 diagnosis were assessed, including 147,715 (31%) during which a COVID-19 antiviral was prescribed”
Only 31% got antivirals
Raykin J et al. COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years - United States, June 1, 2023-September 30, 2025. MMWR. Morbidity and mortality weekly report. 2026.
From the study: “16%–23% of outpatients aged ≥65 years with COVID-19 received an antiviral prescription during periods of low COVID-19 incidence compared with 37%–38% during higher incidence periods”
Only 31% got antivirals
Raykin J et al. COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years - United States, June 1, 2023-September 30, 2025. MMWR. Morbidity and mortality weekly report. 2026.
From the study: “Persons with at least one comorbidity and rural residents had lower odds of receiving an antiviral prescription.”
Only 31% got antivirals
Raykin J et al. COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years - United States, June 1, 2023-September 30, 2025. MMWR. Morbidity and mortality weekly report. 2026.
Nearly a quarter of independent seniors hospitalized for COVID-19 needed new care.
1 in 4 needed new careFrom about 23% of previously independent patients 65+ who developed new care needs
Among adults 65 and older hospitalized with COVID-19 in Nara, Japan, most who had been independent stayed that way, but about 23% developed new long-term care needs. One year after admission, 80.9% were alive overall: 93.6% of those aged 65-69, but only 56.6% of those 90 and older.
Surviving the hospital is not the whole story for older adults: some come home needing daily help they did not need before, and the very oldest face high odds of dying within a year. Insurance and care-needs records from one Japanese prefecture, 2020–2022, with no uninfected comparison group for care needs, so not all decline can be pinned on COVID-19.
See the evidence
A population-based study of 2,175 adults 65 and older hospitalized with COVID-19 in Nara Prefecture, Japan, February 2020 to August 2022, using insurance and care records.
From the study: “While most patients without prior care needs retained independence, approximately 23% developed new care requirements after COVID-19.”
1 in 4 needed new care
Takemoto K et al. One-Year Survival and Changes in Care Needs Among Hospitalized Older Patients With Coronavirus Disease 2019 in Japan: A Nara Kokuho Database Analysis. Geriatrics & gerontology international. 2026.
From the study: “The overall 1-year survival rate was 80.9%.”
1 in 4 needed new care
Takemoto K et al. One-Year Survival and Changes in Care Needs Among Hospitalized Older Patients With Coronavirus Disease 2019 in Japan: A Nara Kokuho Database Analysis. Geriatrics & gerontology international. 2026.
From the study: “Age significantly influenced survival, with rates of 93.6% for patients aged 65-69 years and 56.6% for those ≥ 90 years.”
1 in 4 needed new care
Takemoto K et al. One-Year Survival and Changes in Care Needs Among Hospitalized Older Patients With Coronavirus Disease 2019 in Japan: A Nara Kokuho Database Analysis. Geriatrics & gerontology international. 2026.
Dementia associations were recorded in older adults with diabetes
Documented COVID was associated with higher hazards of new dementia and vascular dementia versus matched unexposed adults with type 2 diabetes.
Both results concern type 2 diabetes. New dementia specifies age 65 years or older; vascular dementia specifies older adults. Observational matching cannot establish cause, and diagnostic coding can miss unrecorded infections.
The selected diabetes cohort also had stroke and mortality associations
Among older adults with type 2 diabetes, documented COVID was associated with higher hazards of ischemic stroke and death from any cause than in matched unexposed adults.
The cerebral-infarction finding concerns adults aged 65 years or older. These observational hazard comparisons are not absolute probabilities and do not establish that infection caused the outcomes.
Study details & original results
Chen, I-Wen et al.. Long-term risk of incident dementia following documented COVID-19 among older adults with type 2 diabetes: a propensity score-matched cohort study.. Frontiers in aging neuroscience. 2026.
Incident overall dementia among propensity score-matched adults aged 65 years or older with T2DM and documented COVID-19 versus an unexposed cohort
HR 1.51 95% CI: 1.47-1.55
Vascular dementia among propensity score-matched older adults with T2DM and documented COVID-19 versus an unexposed cohort
Long-term-care residents had higher mortality than community residents
4.6-fold higher
A US review reported 4.6-fold higher mortality among long-term-care-facility residents than community-dwelling individuals.
All reviewed studies included Omicron-period data, but most also covered earlier variants. This is not an Omicron-only estimate or an individual's current mortality probability.
Approximately 1 in 6
Care-facility residents accounted for a share of COVID hospitalizations
Approximately 1 in 6 COVID-19 hospitalizations in the reviewed US evidence occurred among long-term-care-facility residents.
The denominator is COVID-19 hospitalizations, not facility residents. All studies included Omicron-period data, but most also covered earlier variants.
Study details & original results
Gravenstein, Stefan et al.. Current Impact of COVID-19 in Long-Term Care Facilities in the United States: A Systematic Literature Review.. The Senior care pharmacist. 2026.
Mortality among LTCF residents compared with community-dwelling individuals in the reviewed U.S. evidence; all studies included Omicron-period data, but most also covered earlier variants.
Proportion of COVID-19 hospitalizations occurring among LTCF residents in the reviewed U.S. evidence; all studies included Omicron-period data, but most also covered earlier variants.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 10 findingsOriginal results, comparisons and study details.
2 of 2 source groupsFindings stay together with their study.
SOURCE 027 findings
Chen, I-Wen et al.. Long-term risk of incident dementia following documented COVID-19 among older adults with type 2 diabetes: a propensity score-matched cohort study.. Frontiers in aging neuroscience. 2026.
Overall dementia among propensity score-matched older adults with T2DM and documented COVID-19 versus an unexposed cohort, across sequential landmark periods
Gravenstein, Stefan et al.. Current Impact of COVID-19 in Long-Term Care Facilities in the United States: A Systematic Literature Review.. The Senior care pharmacist. 2026.
Weekly COVID-19 infection and hospitalization incidence among U.S. nursing home residents; all reviewed studies included Omicron-period data, but most also included earlier variant periods.
Added
614-1338 infections and 38-71 hospitalizations per 1,000 residents per weekSource [1]
Proportion of COVID-19 hospitalizations occurring among LTCF residents in the reviewed U.S. evidence; all studies included Omicron-period data, but most also covered earlier variants.
Mortality among LTCF residents compared with community-dwelling individuals in the reviewed U.S. evidence; all studies included Omicron-period data, but most also covered earlier variants.
Browse the 10 original sourcesThe complete bibliography behind this monitor.
[1]
Gravenstein, Stefan et al.. Current Impact of COVID-19 in Long-Term Care Facilities in the United States: A Systematic Literature Review.. The Senior care pharmacist. 2026.
Chen, I-Wen et al.. Long-term risk of incident dementia following documented COVID-19 among older adults with type 2 diabetes: a propensity score-matched cohort study.. Frontiers in aging neuroscience. 2026.
Levin AT et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. European journal of epidemiology. 2020.
Gilstrap L et al. Trends in Mortality Rates Among Medicare Enrollees With Alzheimer Disease and Related Dementias Before and During the Early Phase of the COVID-19 Pandemic. JAMA neurology. 2022.
Chen R et al. Excess Mortality With Alzheimer Disease and Related Dementias as an Underlying or Contributing Cause During the COVID-19 Pandemic in the US. JAMA neurology. 2023.
Gravenstein S et al. Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination. Journal of the American Medical Directors Association. 2026.
Raykin J et al. COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years - United States, June 1, 2023-September 30, 2025. MMWR. Morbidity and mortality weekly report. 2026.
Takemoto K et al. One-Year Survival and Changes in Care Needs Among Hospitalized Older Patients With Coronavirus Disease 2019 in Japan: A Nara Kokuho Database Analysis. Geriatrics & gerontology international. 2026.
Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results. Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed.
Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.
These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.
The October 2026 COVID citation audit found errors in this collection. These downloads may still contain affected findings and bibliography entries. Read the correction record before using them.
“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.
For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.